KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income (2016 - 2025)

Historic Net Income for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Net Income rose 11913.63% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10333.39%. This contributed to the annual value of $226.5 million for FY2024, which is 46919.75% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Net Income of $71.8 million as of Q3 2025, which was up 11913.63% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Net Income registered a high of $143.8 million during Q4 2024, and its lowest value of -$113.1 million during Q1 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Net Income had a median value of -$14.5 million in 2021 and averaged -$5.3 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 13948.56% in 2023, then skyrocketed by 289820.47% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Net Income stood at -$43.1 million in 2021, then rose by 3.29% to -$41.7 million in 2022, then soared by 209.77% to $45.7 million in 2023, then soared by 214.23% to $143.8 million in 2024, then plummeted by 50.05% to $71.8 million in 2025.
  • Its Net Income was $71.8 million in Q3 2025, compared to $26.7 million in Q2 2025 and $19.0 million in Q1 2025.